The efficacy of licorice root extract in decreasing transaminase activities in non-alcoholic fatty liver disease: A randomized controlled clinical trial

Phytotherapy Research

Volumn 26, Issue 9, 2012, Pages 1381-1384

  Hajiaghamohammadi, Ali Akbar ^a,b   Ziaee, Amir ^b   Samimi, Rasoul ^a  

^a QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Qazvin Research Center for Metabolic Diseases   (Iran)

Author keywords

glycyrrhizin; licorice root; NAFLD; NASH; non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLYCYRRHIZA EXTRACT; LIVER ENZYME; PLACEBO;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; ECHOGRAPHY; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID STORAGE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; DOUBLE-BLIND METHOD; FATTY LIVER; FEMALE; GLYCYRRHIZA; HUMANS; LIVER; MALE; MIDDLE AGED; PLANT EXTRACTS; PLANT ROOTS; YOUNG ADULT;

GLYCYRRHIZA;

EID: 84866103604     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3728     Document Type: Article

References (33)

1. Amarapurkar DN, Hashimoto E, Lesmana LA, et al., 2007. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 22: 788-793
2. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F,. 2007. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 1: CD005166.
3. Aoki F, Honda S, Kishida H, et al., 2007. Suppression by licorice flavonoids of abdominal fat accumulation and body weight gain in high-fat diet-induced obese C57BL/6J mice. Biosci Biotechnol Biochem 71: 206-214.
4. Bernard S, Touzet S, Personne I, et al., 2000. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 43: 995-9
5. Chalton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS,. 2002. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 35: 898.
6. Chande N, Laidlaw M, Adams P, Marotta P,. 2006. Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study. Dig Dis Sci 51: 1183-1189.
7. Chitturi S, Abeygunasekera S, Farrell GC, et al., 2002. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance: syndrome. Hepatology 35: 373.
8. Chitturi S, Farrell GC, Hashimoto E, et al., 2007. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol 22: 778-787.
9. Choudhury J, Sanyal AJ,. 2004. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 8: 575.
10. Day CP, James OF,. 1998. Steatohepatitis: a tale of two 'hits'? Gastroenterology 114: 842.
11. Eu CH, Lim WY, Ton SH, bin Abdul Kadir K,. 2010. Glycyrrhizic acid improved lipoprotein lipase expression, insulin sensitivity, serum lipid and lipid deposition in high-fat diet-indused obese rats. Lipids Health Dis 9: 81.
12. George DK, Goldwurm S, MacDonald GA, et al., 1998. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114: 311.
13. Hajaghamohammadi AA, Ziaee A, Rafiei R,. 2008. The efficacy of silymarin in decreasing transaminase activities in NAFLD: A randomized controlled clinical trial. Hepatitis Mon J 8: 191-195.
14. Hauteland JW, Konopski Z, Eggesb HB, et al., 2009. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 44: 853-860.
15. Hickman, IJ, Jonsson, JR, Prins, JB, et al., 2004. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53: 413-419
16. Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y,. 1995. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 9: 101-105.
17. Lavine JE,. 2000. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr 136: 734-738.
18. Lavine JE, Schwimmer JB, Van Natta ML, et al., 2011. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305: 1659-1668.
19. Lim WY, Chia YY, Liong SY, et al., 2009. lipoprotein lipase expression, serum lipid and tissue lipid deposition in orally -administered glycyrrhizic acid- treated rats. Lipids Health Dis 8: 31.
20. Ludwig J, Viggiano TR, McGill DB, Oh BJ,. 1980. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434-438.
21. Mishra P, Younossi ZM,. 2007. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 102: 2716-2717.
22. Noguchi H, Tazawa Y, Nishinomiya F, Takada G,. 1995. The relationship between serum transaminase activities and fatty liver in children with simple obesity. Acta Paediatr Jpn 37: 621-625.
23. Promrat K, Kleiner DE, Niemeier HM, et al., 2010. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51: 121-129
24. Ratziu V, Charloth F, Bemhardt C, et al., 2010. LIDO Study Group, Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51: 366-369
25. Roldan E, Favila R, Martinez M, Uribe M, Méndez-Sánchez N,. 2008. Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver, disease. Ann Hepatol 7: 212-220.
26. Sanyal, A, Chalasani, N, Kowdley, KV, et al., 2010. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1675-1685
27. Shen L, Fan JG, Shao Y, et al., 2003. Prevalence of non alcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 9: 1106.
28. Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H,. 2009. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 48: 587-595.
29. Sonsuz A, Basaranoglu M, Ozbay G,. 2000. Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 95: 1370-1371.
30. Wanless IR, Lentz JS,. 1990. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12: 1106-1110.
31. Williams CD, Stengel J, Asike MI, et al., 2011. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140: 124-131.
32. Wu X, Zhang S, Gurley E, et al., 2008. Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 47: 1905-1915.
33. Zelber-Sagi S, Kessler A, Brazowsky E, et al., 2006. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol 4: 639-644.